BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

SCHEDULE OF DISAGGREGATED REVENUE

For the three and nine months ended September 30, 2024 and 2023, the Company had the following disaggregated revenue:

	Three Months Ended September 30,										Nine Months Ended September 30,
	2024		%			2023		%			2024		%			2023		%
Telehealth product and subscription revenue	$	20,250,592		38	%	$	22,432,989		58	%	$	62,034,621		42	%	$	64,193,130		60	%
LifeMD PC subscription revenue		20,024,954		37	%		1,909,800		5	%		41,514,636		28	%		2,703,589		2	%
WorkSimpli revenue		13,117,611		25	%		14,271,122		37	%		39,650,009		27	%		40,790,439		38	%
Medifast collaboration revenue		-		-	%		-		-	%		5,000,000		3	%		-		-	%
Total net revenue	$	53,393,157		100	%	$	38,613,911		100	%	$	148,199,266		100	%	$	107,687,158		100	%

SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY

The following table summarizes deferred revenue activities for the periods presented:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Beginning of period	$	15,161,659		$	5,668,210		$	8,828,598		$	5,547,506
Additions		49,937,216			38,335,297			144,979,731			103,301,114
Revenue recognized		(48,708,334	)		(37,764,153	)		(137,417,788	)		(102,609,266	)
End of period	$	16,390,541		$	6,239,354		$	16,390,541		$	6,239,354

SUMMARY OF INVENTORY

As of September 30, 2024 and December 31, 2023, the Company’s inventory consisted of the following:

	September 30,			December 31,
	2024			2023
Finished goods	$	1,594,216		$	1,216,833
Raw materials and packaging components		1,316,042			1,898,784
Inventory reserve		(264,815	)		(355,685	)
Total inventory, net	$	2,645,443		$	2,759,932

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price could be less than the average market price of the common shares:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Series B Preferred Stock		-		-		-		995,994
RSUs and RSAs		2,394,915		2,954,750		2,329,055		2,545,875
Stock options		1,397,000		2,616,722		1,694,583		3,316,909
Warrants		1,743,730		4,827,380		1,960,189		4,827,380
Convertible long-term debt		671,141		1,342,282		671,141		1,342,282
Potentially dilutive securities		6,206,786		11,741,134		6,654,968		13,028,440